Atorvastatin delays murine platelet activation in vivo even in the absence of endothelial NO synthase

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 11, 2012, Pages 2609-2615

  Ni, Ran ^a   Peleg, Tal ^a   Gross, Peter L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Atorvastatin; Endothelial NO synthase; Intravital microscopy; Platelet activation; Prenylation; Protease activated receptor 4

Indexed keywords

ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PEPTIDE DERIVATIVE; PROTEINASE ACTIVATED RECEPTOR 4; PROTEINASE ACTIVATED RECEPTOR AGONIST PEPTIDE; THROMBIN; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; CYCLIC GMP; GLYCOPROTEIN IIB; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NOS3 PROTEIN, MOUSE; PROTEASE-ACTIVATED RECEPTOR 4; PYRROLE DERIVATIVE; THROMBIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOCYTE ACTIVATION; TREATMENT DURATION; WILD TYPE; ANIMAL; BLOOD CLOTTING PARAMETERS; C57BL MOUSE; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; ORAL DRUG ADMINISTRATION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; TIME;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PLATELETS; CYCLIC GMP; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET MEMBRANE GLYCOPROTEIN IIB; PYRROLES; RECEPTORS, THROMBIN; SIGNAL TRANSDUCTION; THROMBIN; TIME FACTORS;

EID: 84871878568     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300090     Document Type: Article

References (42)

1. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfeld M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicen-tre randomised controlled trial. Drugs. 2004;64:43-60.
2. Calabrò P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol. 2005;20:541-546.
3. Ray JG. Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulm Med. 2003;9:378-384.
4. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Leo A, Cercignani M, Palazzuoli A, Auteri A, Bruni F. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost. 2003;90:476-482.
5. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, Bruni F. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest. 2002;32:901-908.
6. Alfon J, Pueyo Palazon C, Royo T, Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost. 1999;81:822-827.
7. Thompson PD, Moyna NM, White CM, Weber KM, Giri S, Waters DD. The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation. Atherosclerosis. 2002;161:301-306.
8. Gaddam V, Li DY, Mehta JL. Anti-thrombotic effects of atorvastatin-an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther. 2002;7:247-253.
9. Schirmer SH, Werner CM, Laufs U, Böhm M. Nitric oxide-donating statins: a new concept to boost the lipid-independent effects. Cardiovasc Res. 2012;94:395-397.
10. Gertz K, Laufs U, Lindauer U, Nickenig G, Böhm M, Dirnagl U, Endres M. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34:551-557.
11. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endo-thelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002;942:23-30.
12. Laufs U, Gertz K, Huang P, Nickenig G, Böhm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in nor-mocholesterolemic mice. Stroke. 2000;31:2442-2449.
13. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
14. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057-1058.
15. Freedman JE, Loscalzo J. Nitric oxide and its relationship to thrombotic disorders. J Thromb Haemost. 2003;1:1183-1188.
16. Freedman JE, Sauter R, Battinelli EM, Ault K, Knowles C, Huang PL, Loscalzo J. Defcient platelet-derived nitric oxide and enhanced hemo-stasis in mice lacking the NOSIII gene. Circ Res. 1999;84:1416-1421.
17. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997;100:350-356.
18. Kroll MH, Sullivan M. Mechanisms of platelet activation. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage. Baltimore, MD: Williams & Wilkins; 1998:261-294.
19. Loscalzo J. Nitric oxide insuffciency, platelet activation, and arterial thrombosis. Circ Res. 2001;88:756-762.
20. Pigazzi A, Heydrick S, Folli F, Benoit S, Michelson A, Loscalzo J. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem. 1999;274:14368-14375.
21. Schäfer A, Fraccarollo D, Eigenthaler M, Tas P, Firnschild A, Frantz S, Ertl G, Bauersachs J. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol. 2005;25:1071-1077.
22. Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Katoh A, Imaizumi T. HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats. J Cardiovasc Pharmacol. 2005;45:375-381.
23. Chou TC, Lin YF, Wu WC, Chu KM. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin. Br J Pharmacol. 2008;153:1281-1287.
24. Rand ML, Wang H, Pluthero FG, Stafford AR, Ni R, Vaezzadeh N, Allison AC, Kahr WH, Weitz JI, Gross PL. Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affnity and is a potent inhibitor of platelet-mediated events during thrombus formation. J Thromb Haemost. 2012;10:1109-1119.
25. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fbrin during arterial thrombus formation in the mouse. Nat Med. 2002;8:1175-1181.
26. Black AE, Sinz MW, Hayes RN, Woolf TF. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl- CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 1998;26:755-763.
27. Shum YY, Huang N, Whitfeld LR. Pharmacokinetics of atorvastatin in rodents. Pharm Res. 1996;13:S486.
28. Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss HP, Rauch U. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is suffcient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007;49:1035-1042.
29. Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Antiplatelet actions of statins and fbrates are mediated by PPARs. Arterioscler Thromb Vasc Biol. 2009;29:706-711.
30. Obi C, Wysokinski W, Karnicki K, Owen WG, McBane RD 2nd. Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscler Thromb Vasc Biol. 2009;29:1271-1276.
31. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, patho-physiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
32. Emerson M, Momi S, Paul W, Alberti PF, Page C, Gresele P. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb Haemost. 1999;81:961-966.
33. Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost. 1999;82:1390-1394.
34. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation. 2002;105:933-938.
35. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension. 2004;44:186-190.
36. Yamakuchi M, Greer JJ, Cameron SJ, Matsushita K, Morrell CN, Talbot-Fox K, Baldwin WM 3rd, Lefer DJ, Lowenstein CJ. HMG-CoA reduc-tase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res. 2005;96:1185-1192.
37. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-1714.
38. Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, Tanguay JF, Hennekens CH. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol. 2006;97:1332-1336.
39. Fenton JW 2nd, Brezniak DV, Ofosu FA, Shen GX, Jacobson JR, Garcia JG. Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:115-120.
40. Fenton JW 2nd, Jeske WP, Catalfamo JL, Brezniak DV, Moon DG, Shen GX. Statin drugs and dietary isoprenoids downregulate protein prenyl-ation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry Mosc. 2002;67:85-91.
41. Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. Par4 is required for platelet thrombus propagation but not fbrin generation in a mouse model of thrombosis. Proc Natl Acad Sci USA. 2007;104:288-292.
42. Kretz CA, Vaezzadeh N, Gross PL. Tissue factor and thrombosis models. Arterioscler Thromb Vasc Biol. 2010;30:900-908.